BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26422094)

  • 1. Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease.
    Omari T; Davidson G; Bondarov P; Nauclér E; Nilsson C; Lundborg P
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S2-8. PubMed ID: 26422094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease.
    Omari T; Davidson G; Bondarov P; Nauclér E; Nilsson C; Lundborg P
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S2-8. PubMed ID: 26121346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease.
    Omari T; Davidson G; Bondarov P; Nauclér E; Nilsson C; Lundborg P
    J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):530-7. PubMed ID: 18030229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroesophageal Acid Reflux Control 5 Years After Antireflux Surgery, Compared With Long-term Esomeprazole Therapy.
    Hatlebakk JG; Zerbib F; Bruley des Varannes S; Attwood SE; Ell C; Fiocca R; Galmiche JP; Eklund S; Långström G; Lind T; Lundell LR;
    Clin Gastroenterol Hepatol; 2016 May; 14(5):678-85.e3. PubMed ID: 26226096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients.
    Davidson G; Wenzl TG; Thomson M; Omari T; Barker P; Lundborg P; Illueca M
    J Pediatr; 2013 Sep; 163(3):692-8.e1-2. PubMed ID: 23800403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett's esophagus.
    Yeh RW; Gerson LB; Triadafilopoulos G
    Dis Esophagus; 2003; 16(3):193-8. PubMed ID: 14641308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
    Tolia V; Gilger MA; Barker PN; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26422096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esomeprazole for the Treatment of GERD in Infants Ages 1-11 Months.
    Winter H; Gunasekaran T; Tolia V; Gottrand F; Barker PN; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S9-15. PubMed ID: 26422097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.
    Vasiliadis KV; Viazis N; Vlachogiannakos J; Sgouros SN; Stefanidis G; Archimandritis A; Karamanolis DG
    Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Tolerability of Esomeprazole in Children With Gastroesophageal Reflux Disease.
    Gilger MA; Tolia V; Vandenplas Y; Youssef NN; Traxler B; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S16-23. PubMed ID: 26422093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
    Tolia V; Gilger MA; Barker PN; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26121348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response.
    Earp JC; Mehrotra N; Peters KE; Fiorentino RP; Griebel D; Lee SC; Mulberg A; Röhss K; Sandström M; Taylor A; Tornøe CW; Wynn EL; Van der Walt JS; Garnett C
    J Pediatr Gastroenterol Nutr; 2017 Sep; 65(3):272-277. PubMed ID: 27875488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.
    Sandström M; Davidson G; Tolia V; Sullivan JE; Långström G; Lundborg P; Brown K
    Clin Ther; 2012 Aug; 34(8):1828-38. PubMed ID: 22832034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reflux episodes detected by impedance in patients on and off esomeprazole: a randomised double-blinded placebo-controlled crossover study.
    Moawad FJ; Betteridge JD; Boger JA; Cheng FK; Belle LS; Chen YJ; Maydonovitch CL; Wong RK
    Aliment Pharmacol Ther; 2013 May; 37(10):1011-8. PubMed ID: 23560727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The impact of proton pump inhibitors on esophageal acid exposure in gastroesophageal reflux disease].
    Liang XY; Chen WN; Lan L; Wang Q; Lü YW; Lan Y
    Zhonghua Nei Ke Za Zhi; 2012 Jul; 51(7):513-5. PubMed ID: 22943821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esomeprazole for the Treatment of GERD in Infants Ages 1-11 Months.
    Winter H; Gunasekaran T; Tolia V; Gottrand F; Barker PN; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S9-15. PubMed ID: 26121349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Tolerability of Esomeprazole in Children With Gastroesophageal Reflux Disease.
    Gilger MA; Tolia V; Vandenplas Y; Youssef NN; Traxler B; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S16-23. PubMed ID: 26121345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of antireflux treatment on the frequency of awakenings from sleep in patients with Gastroesophageal reflux disease.
    Jha LK; Maradey-Romero C; Gadam R; Hershcovici T; Fass OZ; Quan SF; Guillen J; Fass R
    Neurogastroenterol Motil; 2015 Feb; 27(2):237-45. PubMed ID: 25484104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: a post hoc analysis of the LOTUS trial.
    Lundell L; Hatlebakk J; Galmiche JP; Attwood SE; Ell C; Fiocca R; Persson T; Nagy P; Eklund S; Lind T
    Curr Med Res Opin; 2015 Jan; 31(1):65-73. PubMed ID: 25350223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease.
    Omari T; Lundborg P; Sandström M; Bondarov P; Fjellman M; Haslam R; Davidson G
    J Pediatr; 2009 Aug; 155(2):222-8. PubMed ID: 19394048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.